Schroder Investment Management Group Sells 354,483 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Schroder Investment Management Group cut its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 64.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 196,359 shares of the biopharmaceutical company's stock after selling 354,483 shares during the quarter. Schroder Investment Management Group's holdings in Royalty Pharma were worth $5,009,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of RPRX. Franklin Resources Inc. boosted its holdings in Royalty Pharma by 5.0% during the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company's stock valued at $40,705,000 after acquiring an additional 70,130 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Royalty Pharma by 4.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock valued at $79,888,000 after buying an additional 130,025 shares during the period. Pallas Capital Advisors LLC bought a new stake in shares of Royalty Pharma in the fourth quarter valued at about $2,355,000. Jupiter Asset Management Ltd. bought a new stake in shares of Royalty Pharma in the fourth quarter valued at about $4,950,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in Royalty Pharma by 303.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company's stock worth $13,926,000 after purchasing an additional 406,123 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RPRX has been the subject of several recent analyst reports. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $41.60.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock traded down $1.11 during midday trading on Thursday, reaching $31.16. The company had a trading volume of 1,020,490 shares, compared to its average volume of 3,207,322. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $17.96 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. The stock has a fifty day simple moving average of $32.49 and a 200 day simple moving average of $29.08. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities research analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.